Korenaga Masaaki, Nishina Sohji, Korenaga Keiko, Tomiyama Yasuyuki, Yoshioka Naoko, Hara Yuichi, Sasaki Yusuke, Shimonaka Yasushi, Hino Keisuke
Department of Hepatology and Pancreatology, Kawasaki Medical School, Okayama, Japan; The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine (NCGM), Chiba, Japan.
Liver Int. 2015 Apr;35(4):1303-14. doi: 10.1111/liv.12675. Epub 2014 Sep 18.
BACKGROUND & AIMS: Branched-chain amino acids (BCAA) reduce the incidence of hepatocellular carcinoma (HCC) in patients with cirrhosis. However, the mechanisms that underlie these effects remain unknown. Previously, we reported that oxidative stress in male transgenic mice that expressed hepatitis C virus polyprotein (HCVTgM) caused hepatic iron accumulation by reducing hepcidin transcription, thereby leading to HCC development. This study investigated whether long-term treatment with BCAA reduced hepatic iron accumulation and oxidative stress in iron-overloaded HCVTgM and in patients with HCV-related advanced fibrosis.
Male HCVTgM were fed an excess-iron diet that comprised either casein or 3.0% BCAA, or a control diet, for 6 months.
For HCVTgM, BCAA supplementation increased the serum hepcidin-25 levels and antioxidant status [ratio of biological antioxidant potential (BAP) relative to derivatives of reactive oxygen metabolites (dROM)], decreased the hepatic iron contents, attenuated reactive oxygen species generation, and restored mitochondrial superoxide dismutase expression and mitochondrial complex I activity in the liver compared with mice fed the control diet. After 48 weeks of BCAA supplementation in patients with HCV-related advanced fibrosis, BAP/dROM and serum hepcidin-25 increased and serum ferritin decreased compared with the pretreatment levels.
BCAA supplementation reduced oxidative stress by restoring mitochondrial function and improved iron metabolism by increasing hepcidin-25 in both iron-overloaded HCVTgM and patients with HCV-related advanced fibrosis. These activities of BCAA may partially account for their inhibitory effects on HCC development in cirrhosis patients.
支链氨基酸(BCAA)可降低肝硬化患者肝细胞癌(HCC)的发生率。然而,这些作用的潜在机制尚不清楚。此前,我们报道过,表达丙型肝炎病毒多聚蛋白的雄性转基因小鼠(HCVTgM)中的氧化应激通过降低铁调素转录导致肝脏铁蓄积,进而引发HCC的发生。本研究调查了长期使用BCAA治疗是否能减少铁过载的HCVTgM以及丙型肝炎病毒相关晚期纤维化患者的肝脏铁蓄积和氧化应激。
给雄性HCVTgM喂食含酪蛋白或3.0% BCAA的高铁饮食或对照饮食,持续6个月。
对于HCVTgM,与喂食对照饮食的小鼠相比,补充BCAA可提高血清铁调素-25水平和抗氧化状态[生物抗氧化潜能(BAP)与活性氧代谢产物衍生物(dROM)的比值],降低肝脏铁含量,减弱活性氧生成,并恢复肝脏线粒体超氧化物歧化酶表达和线粒体复合物I活性。在丙型肝炎病毒相关晚期纤维化患者补充BCAA 48周后,与治疗前水平相比,BAP/dROM和血清铁调素-25升高,血清铁蛋白降低。
补充BCAA可通过恢复线粒体功能减轻氧化应激,并通过增加铁调素-25改善铁代谢,在铁过载的HCVTgM和丙型肝炎病毒相关晚期纤维化患者中均如此。BCAA的这些作用可能部分解释了它们对肝硬化患者HCC发生的抑制作用。